Search

Your search keyword '"Doroshow, Deborah B."' showing total 33 results
Start Over Author "Doroshow, Deborah B."
33 results on '"Doroshow, Deborah B."'

1. An IL-4 signalling axis in bone marrow drives pro-tumorigenic myelopoiesis

Author

LaMarche, Nelson M., Hegde, Samarth, Park, Matthew D., Maier, Barbara B., Troncoso, Leanna, Le Berichel, Jessica, Hamon, Pauline, Belabed, Meriem, Mattiuz, Raphaël, Hennequin, Clotilde, Chin, Theodore, Reid, Amanda M., Reyes-Torres, Iván, Nemeth, Erika, Zhang, Ruiyuan, Olson, Oakley C., Doroshow, Deborah B., Rohs, Nicholas C., Gomez, Jorge E., Veluswamy, Rajwanth, Hall, Nicole, Venturini, Nicholas, Ginhoux, Florent, Liu, Zhaoyuan, Buckup, Mark, Figueiredo, Igor, Roudko, Vladimir, Miyake, Kensuke, Karasuyama, Hajime, Gonzalez-Kozlova, Edgar, Gnjatic, Sacha, Passegué, Emmanuelle, Kim-Schulze, Seunghee, Brown, Brian D., Hirsch, Fred R., Kim, Brian S., Marron, Thomas U., and Merad, Miriam

Published
2024
Full Text
View/download PDF

3. A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19:CCC19 Governance, Protocol, and Quality Assurance

Author

Abidi, Maheen, Aboulafia, David M, Accordino, Melissa K, Acoba, Jared D, Ahluwalia, Manmeet S, Ahmad, Syed A, Ajmera, Archana, Alimohamed, Saif I, Altman, Jessica, Angevine, Anne H, Bakouny, Ziad, Bar, Michael H, Bardia, Aditya, Barnholtz-Sloan, Jill S, Barrow McCollough, Briana, Bashir, Babar, Batist, Gerald, Bekaii-Saab, Tanios S, Berg, Stephanie, Bernicker, Eric H, Bhutani, Divaya, Bilen, Mehmet A, Bindal, Poorva, Bishnoi, Rohit, Blau, Sibel, Bohachek, Pamela, Boland, Genevieve, Bonnen, Mark, Bouchard, Gabrielle, Bouganim, Nathaniel, Bowles, Daniel W, Busser, Fiona J, Butt, Omar, Cabal, Angelo, Cabalona, Wilhelmina D, Cabebe, Elwyn C, Caimi, Paolo, Campian, Jian L, Carducci, Theresa M, Chen, James L, Cheng, Alex, Chism, David D, Choueiri, Toni K, Clark, Melanie J, Clement, Jessica M, Connors, Jean M, Cook, Erin, Curran, Catherine R, Daher, Ahmad, Dailey, Mark E, Davis, Elizabeth J, Dawsey, Scott J, Deeken, John F, Del Prete, Salvatore A, Demetri, George D, Desai, Aakash, Doroshow, Deborah B, Durbin, Eric B, Egan, Pamela C, Elias, Rawad, Elkrief, Arielle, Elms, Destry J, Elshoury, Amro, Faller, Bryan, Farmakiotis, Dimitrios, Fecher, Leslie A, Feldman, Lawrence E, Ferrario, Cristiano, Fiala, Mark A, Flora, Daniel B, French, Benjamin, Friese, Christopher R, Fu, Julie C, Gadgeel, Shirish M, Gainor, Justin, Galsky, Matthew D, Gantt, Gerald, Garcia, Jorge A, Gartrell, Benjamin A, Gatti-Mays, Margaret E, Gill, David M, Gillaspie, Erin A, Giordano, Antonio, Glace, Mary Grace, Glover, Michael J, Goel, Sanjay, Graber, Jerome J, Griffiths, Elizabeth A, Grivas, Petros, Grover, Punita, Gulati, Anthony P, Gulati, Shuchi, Gupta, Shilpa, Gurley, Michael, Hafez, Navid, Halabi, Susan, Halfdanarson, Thorvardur R, Halmos, Balazs, Hausrath, Daniel J, and Hawley, Jessica E

Subjects
Biochemistry and Cell Biology, Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Biological Sciences, Clinical Research, Cancer, COVID-19, COVID-19 Testing, Data Accuracy, Electronic Health Records, Humans, Neoplasms, Quality Improvement, SARS-CoV-2, COVID-19 and Cancer Consortium. Electronic address: jeremy.warner@vumc.org, COVID-19 and Cancer Consortium, Neurosciences, Oncology & Carcinogenesis, Biochemistry and cell biology, Oncology and carcinogenesis
Abstract

When the COVID-19 pandemic began, formal frameworks to collect data about affected patients were lacking. The COVID-19 and Cancer Consortium (CCC19) was formed to collect granular data on patients with cancer and COVID-19 at scale and as rapidly as possible. CCC19 has grown from five initial institutions to 125 institutions with >400 collaborators. More than 5,000 cases with complete baseline data have been accrued. Future directions include increased electronic health record integration for direct data ingestion, expansion to additional domestic and international sites, more intentional patient involvement, and granular analyses of still-unanswered questions related to cancer subtypes and treatments.

Published
2020

4. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

Author

Kuderer, Nicole M, Choueiri, Toni K, Shah, Dimpy P, Shyr, Yu, Rubinstein, Samuel M, Rivera, Donna R, Shete, Sanjay, Hsu, Chih-Yuan, Desai, Aakash, de Lima Lopes, Gilberto, Grivas, Petros, Painter, Corrie A, Peters, Solange, Thompson, Michael A, Bakouny, Ziad, Batist, Gerald, Bekaii-Saab, Tanios, Bilen, Mehmet A, Bouganim, Nathaniel, Larroya, Mateo Bover, Castellano, Daniel, Del Prete, Salvatore A, Doroshow, Deborah B, Egan, Pamela C, Elkrief, Arielle, Farmakiotis, Dimitrios, Flora, Daniel, Galsky, Matthew D, Glover, Michael J, Griffiths, Elizabeth A, Gulati, Anthony P, Gupta, Shilpa, Hafez, Navid, Halfdanarson, Thorvardur R, Hawley, Jessica E, Hsu, Emily, Kasi, Anup, Khaki, Ali R, Lemmon, Christopher A, Lewis, Colleen, Logan, Barbara, Masters, Tyler, McKay, Rana R, Mesa, Ruben A, Morgans, Alicia K, Mulcahy, Mary F, Panagiotou, Orestis A, Peddi, Prakash, Pennell, Nathan A, Reynolds, Kerry, Rosen, Lane R, Rosovsky, Rachel, Salazar, Mary, Schmidt, Andrew, Shah, Sumit A, Shaya, Justin A, Steinharter, John, Stockerl-Goldstein, Keith E, Subbiah, Suki, Vinh, Donald C, Wehbe, Firas H, Weissmann, Lisa B, Wu, Julie Tsu-Yu, Wulff-Burchfield, Elizabeth, Xie, Zhuoer, Yeh, Albert, Yu, Peter P, Zhou, Alice Y, Zubiri, Leyre, Mishra, Sanjay, Lyman, Gary H, Rini, Brian I, Warner, Jeremy L, Consortium, COVID-19 and Cancer, Abidi, Maheen, Acoba, Jared D, Agarwal, Neeraj, Ahmad, Syed, Ajmera, Archana, Altman, Jessica, Angevine, Anne H, Azad, Nilo, Bar, Michael H, Bardia, Aditya, Barnholtz-Sloan, Jill, Barrow, Briana, Bashir, Babar, Belenkaya, Rimma, Berg, Stephanie, Bernicker, Eric H, Bestvina, Christine, Bishnoi, Rohit, Boland, Genevieve, Bonnen, Mark, Bouchard, Gabrielle, Bowles, Daniel W, Busser, Fiona, Cabal, Angelo, Caimi, Paolo, and Carducci, Theresa

Subjects
Biomedical and Clinical Sciences, Health Sciences, Clinical Sciences, Oncology and Carcinogenesis, Infectious Diseases, Prevention, Lung, Coronaviruses, Cancer, Emerging Infectious Diseases, Good Health and Well Being, Aged, Antiviral Agents, Azithromycin, Betacoronavirus, COVID-19, Cause of Death, Comorbidity, Coronavirus Infections, Databases, Factual, Female, Humans, Hydroxychloroquine, Male, Middle Aged, Neoplasms, Pandemics, Pneumonia, Viral, Prognosis, Risk Factors, SARS-CoV-2, COVID-19 Drug Treatment, COVID-19 and Cancer Consortium, Medical and Health Sciences, General & Internal Medicine, Biomedical and clinical sciences, Health sciences
Abstract

BackgroundData on patients with COVID-19 who have cancer are lacking. Here we characterise the outcomes of a cohort of patients with cancer and COVID-19 and identify potential prognostic factors for mortality and severe illness.MethodsIn this cohort study, we collected de-identified data on patients with active or previous malignancy, aged 18 years and older, with confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection from the USA, Canada, and Spain from the COVID-19 and Cancer Consortium (CCC19) database for whom baseline data were added between March 17 and April 16, 2020. We collected data on baseline clinical conditions, medications, cancer diagnosis and treatment, and COVID-19 disease course. The primary endpoint was all-cause mortality within 30 days of diagnosis of COVID-19. We assessed the association between the outcome and potential prognostic variables using logistic regression analyses, partially adjusted for age, sex, smoking status, and obesity. This study is registered with ClinicalTrials.gov, NCT04354701, and is ongoing.FindingsOf 1035 records entered into the CCC19 database during the study period, 928 patients met inclusion criteria for our analysis. Median age was 66 years (IQR 57-76), 279 (30%) were aged 75 years or older, and 468 (50%) patients were male. The most prevalent malignancies were breast (191 [21%]) and prostate (152 [16%]). 366 (39%) patients were on active anticancer treatment, and 396 (43%) had active (measurable) cancer. At analysis (May 7, 2020), 121 (13%) patients had died. In logistic regression analysis, independent factors associated with increased 30-day mortality, after partial adjustment, were: increased age (per 10 years; partially adjusted odds ratio 1·84, 95% CI 1·53-2·21), male sex (1·63, 1·07-2·48), smoking status (former smoker vs never smoked: 1·60, 1·03-2·47), number of comorbidities (two vs none: 4·50, 1·33-15·28), Eastern Cooperative Oncology Group performance status of 2 or higher (status of 2 vs 0 or 1: 3·89, 2·11-7·18), active cancer (progressing vs remission: 5·20, 2·77-9·77), and receipt of azithromycin plus hydroxychloroquine (vs treatment with neither: 2·93, 1·79-4·79; confounding by indication cannot be excluded). Compared with residence in the US-Northeast, residence in Canada (0·24, 0·07-0·84) or the US-Midwest (0·50, 0·28-0·90) were associated with decreased 30-day all-cause mortality. Race and ethnicity, obesity status, cancer type, type of anticancer therapy, and recent surgery were not associated with mortality.InterpretationAmong patients with cancer and COVID-19, 30-day all-cause mortality was high and associated with general risk factors and risk factors unique to patients with cancer. Longer follow-up is needed to better understand the effect of COVID-19 on outcomes in patients with cancer, including the ability to continue specific cancer treatments.FundingAmerican Cancer Society, National Institutes of Health, and Hope Foundation for Cancer Research.

Published
2020

5. Cyclin E1/CDK2 activation defines a key vulnerability to WEE1 kinase inhibition in gynecological cancers.

Author

Kim, Daehwan, Chung, Heekyung, Liu, Wen, Jeong, Kangjin, Ozmen, Tugba Y., Ozmen, Furkan, Rames, Matthew J., Kim, Sangyub, Guo, Xiao, Jameson, Nathan, de Jong, Petrus R., Yea, Steven, Harford, Laurie, Li, Jiali, Mathews, Cara A., Doroshow, Deborah B., Charles, Vincent J., Kim, Doris, Fischer, Kimberlee, and Samatar, Ahmed A.

Subjects
MEDICAL sciences, CYCLIN-dependent kinases, CYCLINS, CELL cycle, OVARIAN cancer
Abstract

Upregulation of Cyclin E1 and subsequent activation of CDK2 accelerates cell cycle progression from G1 to S phase and is a common oncogenic driver in gynecological malignancies. WEE1 kinase counteracts the effects of Cyclin E1/CDK2 activation by regulating multiple cell cycle checkpoints. Here we characterized the relationship between Cyclin E1/CDK2 activation and sensitivity to the selective WEE1 inhibitor azenosertib. We found that ovarian cancer cell lines with high levels of endogenous Cyclin E1 expression or forced overexpression were exquisitely sensitive to azenosertib and these results extended to in vivo models of ovarian and uterine serous carcinoma. Models with high Cyclin E1 expression showed higher baseline levels of replication stress and enhanced cellular responses to azenosertib treatment. We found azenosertib synergized with different classes of chemotherapy and described distinct underlying mechanisms. Finally, we provided early evidence from an ongoing phase I study demonstrating the clinical activity of monotherapy azenosertib in patients with Cyclin E1/CDK2-activated ovarian and uterine serous carcinomas. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

8. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

Author

Abidi, Maheen, Acoba, Jared D., Agarwal, Neeraj, Ahmad, Syed, Ajmera, Archana, Altman, Jessica, Angevine, Anne H., Azad, Nilo, Bar, Michael H., Bardia, Aditya, Barnholtz-Sloan, Jill, Barrow, Briana, Bashir, Babar, Belenkaya, Rimma, Berg, Stephanie, Bernicker, Eric H., Bestvina, Christine, Bishnoi, Rohit, Boland, Genevieve, Bonnen, Mark, Bouchard, Gabrielle, Bowles, Daniel W., Busser, Fiona, Cabal, Angelo, Caimi, Paolo, Carducci, Theresa, Casulo, Carla, Chen, James L., Clement, Jessica M, Chism, David, Cook, Erin, Curran, Catherine, Daher, Ahmad, Dailey, Mark, Dahiya, Saurabh, Deeken, John, Demetri, George D., DiLullo, Sandy, Duma, Narjust, Elias, Rawad, Faller, Bryan, Fecher, Leslie A., Feldman, Lawrence E., Friese, Christopher R., Fu, Paul, Fu, Julie, Futreal, Andy, Gainor, Justin, Garcia, Jorge, Gill, David M., Gillaspie, Erin A., Giordano, Antonio, Glace, (Mary) Grace, Grothey, Axel, Gulati, Shuchi, Gurley, Michael, Halmos, Balazs, Herbst, Roy, Hershman, Dawn, Hoskins, Kent, Jain, Rohit K., Jabbour, Salma, Jha, Alokkumar, Johnson, Douglas B., Joshi, Monika, Kelleher, Kaitlin, Kharofa, Jordan, Khan, Hina, Knoble, Jeanna, Koshkin, Vadim S., Kulkarni, Amit A., Lammers, Philip E., Leighton, John C., Jr, Lewis, Mark A., Li, Xuanyi, Li, Ang, Lo, K.M. Steve, Loaiza-Bonilla, Arturo, LoRusso, Patricia, Low, Clarke A., Lustberg, Maryam B., Mahadevan, Daruka, Mansoor, Abdul-Hai, Marcum, Michelle, Markham, Merry Jennifer, Handy Marshall, Catherine, Mashru, Sandeep H., Matar, Sara, McNair, Christopher, McWeeney, Shannon, Mehnert, Janice M., Menendez, Alvaro, Menon, Harry, Messmer, Marcus, Monahan, Ryan, Mushtaq, Sarah, Nagaraj, Gayathri, Nagle, Sarah, Naidoo, Jarushka, Nakayama, John M., Narayan, Vikram, Nelson, Heather H., Nemecek, Eneida R., Nguyen, Ryan, Nuzzo, Pier Vitale, Oberstein, Paul E., Olszewski, Adam J., Owenby, Susie, Pasquinelli, Mary M., Philip, John, Prabhakaran, Sabitha, Puc, Matthew, Ramirez, Amelie, Rathmann, Joerg, Revankar, Sanjay G., Rho, Young Soo, Rhodes, Terence D., Rice, Robert L., Riely, Gregory J., Riess, Jonathan, Rink, Cameron, Robilotti, Elizabeth V., Rosenstein, Lori, Routy, Bertrand, Rovito, Marc A., Saif, M. Wasif, Sanyal, Amit, Schapira, Lidia, Schwartz, Candice, Serrano, Oscar, Shah, Mansi, Shah, Chintan, Shaw, Grace, Shergill, Ardaman, Shouse, Geoffrey, Soares, Heloisa P., Solorzano, Carmen C., Srivastava, Pramod K., Stauffer, Karen, Stover, Daniel G., Stratton, Jamie, Stratton, Catherine, Subbiah, Vivek, Tamimi, Rulla, Tannir, Nizar M., Topaloglu, Umit, Van Allen, Eli, Van Loon, Susan, Vega-Luna, Karen, Venepalli, Neeta, Verma, Amit K., Vikas, Praveen, Wall, Sarah, Weinstein, Paul L., Weiss, Matthias, Wise-Draper, Trisha, Wood, William A., Xu, Wenxin (Vincent), Yackzan, Susan, Zacks, Rosemary, Zhang, Tian, Zimmer, Andrea J., West, Jack, Kuderer, Nicole M, Choueiri, Toni K, Shah, Dimpy P, Shyr, Yu, Rubinstein, Samuel M, Rivera, Donna R, Shete, Sanjay, Hsu, Chih-Yuan, Desai, Aakash, de Lima Lopes, Gilberto, Jr, Grivas, Petros, Painter, Corrie A, Peters, Solange, Thompson, Michael A, Bakouny, Ziad, Batist, Gerald, Bekaii-Saab, Tanios, Bilen, Mehmet A, Bouganim, Nathaniel, Larroya, Mateo Bover, Castellano, Daniel, Del Prete, Salvatore A, Doroshow, Deborah B, Egan, Pamela C, Elkrief, Arielle, Farmakiotis, Dimitrios, Flora, Daniel, Galsky, Matthew D, Glover, Michael J, Griffiths, Elizabeth A, Gulati, Anthony P, Gupta, Shilpa, Hafez, Navid, Halfdanarson, Thorvardur R, Hawley, Jessica E, Hsu, Emily, Kasi, Anup, Khaki, Ali R, Lemmon, Christopher A, Lewis, Colleen, Logan, Barbara, Masters, Tyler, McKay, Rana R, Mesa, Ruben A, Morgans, Alicia K, Mulcahy, Mary F, Panagiotou, Orestis A, Peddi, Prakash, Pennell, Nathan A, Reynolds, Kerry, Rosen, Lane R, Rosovsky, Rachel, Salazar, Mary, Schmidt, Andrew, Shah, Sumit A, Shaya, Justin A, Steinharter, John, Stockerl-Goldstein, Keith E, Subbiah, Suki, Vinh, Donald C, Wehbe, Firas H, Weissmann, Lisa B, Wu, Julie Tsu-Yu, Wulff-Burchfield, Elizabeth, Xie, Zhuoer, Yeh, Albert, Yu, Peter P, Zhou, Alice Y, Zubiri, Leyre, Mishra, Sanjay, Lyman, Gary H, Rini, Brian I, and Warner, Jeremy L

Published
2020
Full Text
View/download PDF

10. An IL-4 signalling axis in bone marrow drives pro-tumorigenic myelopoiesis

Author

LaMarche, Nelson M., primary, Hegde, Samarth, additional, Park, Matthew D., additional, Maier, Barbara B., additional, Troncoso, Leanna, additional, Le Berichel, Jessica, additional, Hamon, Pauline, additional, Belabed, Meriem, additional, Mattiuz, Raphaël, additional, Hennequin, Clotilde, additional, Chin, Theodore, additional, Reid, Amanda M., additional, Reyes-Torres, Iván, additional, Nemeth, Erika, additional, Zhang, Ruiyuan, additional, Olson, Oakley C., additional, Doroshow, Deborah B., additional, Rohs, Nicholas C., additional, Gomez, Jorge E., additional, Veluswamy, Rajwanth, additional, Hall, Nicole, additional, Venturini, Nicholas, additional, Ginhoux, Florent, additional, Liu, Zhaoyuan, additional, Buckup, Mark, additional, Figueiredo, Igor, additional, Roudko, Vladimir, additional, Miyake, Kensuke, additional, Karasuyama, Hajime, additional, Gonzalez-Kozlova, Edgar, additional, Gnjatic, Sacha, additional, Passegué, Emmanuelle, additional, Kim-Schulze, Seunghee, additional, Brown, Brian D., additional, Hirsch, Fred R., additional, Kim, Brian S., additional, Marron, Thomas U., additional, and Merad, Miriam, additional

Published
2023
Full Text
View/download PDF

13. The room where it happens: addressing diversity, equity, and inclusion in National Clinical Trials Network clinical trial leadership

Author

Snyder, Rebecca A, primary, Burtness, Barbara, additional, Cho, May, additional, Del Rivero, Jaydira, additional, Doroshow, Deborah B, additional, Hitchcock, Kathryn E, additional, Kalyan, Aparna, additional, Kim, Christina A, additional, Lukovic, Jelena, additional, Parikh, Aparna R, additional, Sanford, Nina N, additional, Singh, Bhuminder, additional, Shen, Chan, additional, Shroff, Rachna T, additional, Vijayvergia, Namrata, additional, Goodman, Karyn A, additional, and Kunz, Pamela L, additional

Published
2023
Full Text
View/download PDF

15. Systemic Anticancer Therapy and Thromboembolic Outcomes in Hospitalized Patients With Cancer and COVID-19

Author

Gulati, Shuchi, Hsu, Chih-Yuan, Shah, Surbhi, Shah, Pankil K., Zon, Rebecca, Alsamarai, Susan, Awosika, Joy, El-Bakouny, Ziad, Bashir, Babar, Beeghly, Alicia, Berg, Stephanie, de-la-Rosa-Martinez, Daniel, Doroshow, Deborah B., Egan, Pamela C., Fein, Joshua, Flora, Daniel B., Friese, Christopher R., Fromowitz, Ariel, Griffiths, Elizabeth A., Hwang, Clara, Jani, Chinmay, Joshi, Monika, Khan, Hina, Klein, Elizabeth J., Heater, Natalie Knox, Koshkin, Vadim S., Kwon, Daniel H., Labaki, Chris, Latif, Tahir, McKay, Rana R., Nagaraj, Gayathri, Nakasone, Elizabeth S., Nonato, Taylor, Polimera, Hyma V., Puc, Matthew, Razavi, Pedram, Ruiz-Garcia, Erika, Saliby, Renee Maria, Shastri, Aditi, Singh, Sunny R.K., Tagalakis, Vicky, Vilar-Compte, Diana, Weissmann, Lisa B., Wilkins, Cy R., Wise-Draper, Trisha M., Wotman, Michael T., Yoon, James J., Mishra, Sanjay, Grivas, Petros, Shyr, Yu, Warner, Jeremy L., Connors, Jean M., Shah, Dimpy P., Rosovsky, Rachel P., Gulati, Shuchi, Hsu, Chih-Yuan, Shah, Surbhi, Shah, Pankil K., Zon, Rebecca, Alsamarai, Susan, Awosika, Joy, El-Bakouny, Ziad, Bashir, Babar, Beeghly, Alicia, Berg, Stephanie, de-la-Rosa-Martinez, Daniel, Doroshow, Deborah B., Egan, Pamela C., Fein, Joshua, Flora, Daniel B., Friese, Christopher R., Fromowitz, Ariel, Griffiths, Elizabeth A., Hwang, Clara, Jani, Chinmay, Joshi, Monika, Khan, Hina, Klein, Elizabeth J., Heater, Natalie Knox, Koshkin, Vadim S., Kwon, Daniel H., Labaki, Chris, Latif, Tahir, McKay, Rana R., Nagaraj, Gayathri, Nakasone, Elizabeth S., Nonato, Taylor, Polimera, Hyma V., Puc, Matthew, Razavi, Pedram, Ruiz-Garcia, Erika, Saliby, Renee Maria, Shastri, Aditi, Singh, Sunny R.K., Tagalakis, Vicky, Vilar-Compte, Diana, Weissmann, Lisa B., Wilkins, Cy R., Wise-Draper, Trisha M., Wotman, Michael T., Yoon, James J., Mishra, Sanjay, Grivas, Petros, Shyr, Yu, Warner, Jeremy L., Connors, Jean M., Shah, Dimpy P., and Rosovsky, Rachel P.

Abstract

IMPORTANCE: Systematic data on the association between anticancer therapies and thromboembolic events (TEEs) in patients with COVID-19 are lacking. OBJECTIVE: To assess the association between anticancer therapy exposure within 3 months prior to COVID-19 and TEEs following COVID-19 diagnosis in patients with cancer. DESIGN, SETTING, AND PARTICIPANTS: This registry-based retrospective cohort study included patients who were hospitalized and had active cancer and laboratory-confirmed SARS-CoV-2 infection. Data were accrued from March 2020 to December 2021 and analyzed from December 2021 to October 2022. EXPOSURE: Treatments of interest (TOIs) (endocrine therapy, vascular endothelial growth factor inhibitors/tyrosine kinase inhibitors [VEGFis/TKIs], immunomodulators [IMiDs], immune checkpoint inhibitors [ICIs], chemotherapy) vs reference (no systemic therapy) in 3 months prior to COVID-19. MAIN OUTCOMES AND MEASURES: Main outcomes were (1) venous thromboembolism (VTE) and (2) arterial thromboembolism (ATE). Secondary outcome was severity of COVID-19 (rates of intensive care unit admission, mechanical ventilation, 30-day all-cause mortality following TEEs in TOI vs reference group) at 30-day follow-up. RESULTS: Of 4988 hospitalized patients with cancer (median [IQR] age, 69 [59-78] years; 2608 [52%] male), 1869 had received 1 or more TOIs. Incidence of VTE was higher in all TOI groups: endocrine therapy, 7%; VEGFis/TKIs, 10%; IMiDs, 8%; ICIs, 12%; and chemotherapy, 10%, compared with patients not receiving systemic therapies (6%). In multivariable log-binomial regression analyses, relative risk of VTE (adjusted risk ratio [aRR], 1.33; 95% CI, 1.04-1.69) but not ATE (aRR, 0.81; 95% CI, 0.56-1.16) was significantly higher in those exposed to all TOIs pooled together vs those with no exposure. Among individual drugs, ICIs were significantly associated with VTE (aRR, 1.45; 95% CI, 1.01-2.07). Also noted were significant associations between VTE and active and progressing ca

Published
2023

16. Abstract CT199: Rescuing response to ICI by blocking the type-2 immune axis in patients with NSCLC progressing on immunotherapy: A phase 1b/2 trial of dupilumab administered with checkpoint blockade

Author

Marron, Thomas Urban, primary, LaMarche, Nelson M., additional, Park, Matthew D., additional, Hegde, Samarth, additional, Fitzgerald, Bailey, additional, Hennequin, Clotilde, additional, Mattiuz, Raphael, additional, Belabed, Meriem, additional, Berichel, Jessica Le, additional, Maier, Barbara, additional, Hall, Nicole, additional, Miller, Justin, additional, Doroshow, Deborah B., additional, Rohs, Nicholas, additional, Veluswamy, Rajwanth, additional, Venturini, Nicholas, additional, Gomez, Jorge E., additional, Rolfo, Christian, additional, Yankelevitz, David, additional, Chaddha, Udit, additional, Harkin, Timothy, additional, Beasley, Mary B., additional, Kim-schulze, Seunghee, additional, Gnjatic, Sacha, additional, Hirsch, Fred R., additional, and Merad, Miriam, additional

Published
2023
Full Text
View/download PDF

17. Data from Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study

Author

Rivera, Donna R., primary, Peters, Solange, primary, Panagiotou, Orestis A., primary, Shah, Dimpy P., primary, Kuderer, Nicole M., primary, Hsu, Chih-Yuan, primary, Rubinstein, Samuel M., primary, Lee, Brendan J., primary, Choueiri, Toni K., primary, de Lima Lopes, Gilberto, primary, Grivas, Petros, primary, Painter, Corrie A., primary, Rini, Brian I., primary, Thompson, Michael A., primary, Arcobello, Jonathan, primary, Bakouny, Ziad, primary, Doroshow, Deborah B., primary, Egan, Pamela C., primary, Farmakiotis, Dimitrios, primary, Fecher, Leslie A., primary, Friese, Christopher R., primary, Galsky, Matthew D., primary, Goel, Sanjay, primary, Gupta, Shilpa, primary, Halfdanarson, Thorvardur R., primary, Halmos, Balazs, primary, Hawley, Jessica E., primary, Khaki, Ali Raza, primary, Lemmon, Christopher A., primary, Mishra, Sanjay, primary, Olszewski, Adam J., primary, Pennell, Nathan A., primary, Puc, Matthew M., primary, Revankar, Sanjay G., primary, Schapira, Lidia, primary, Schmidt, Andrew, primary, Schwartz, Gary K., primary, Shah, Sumit A., primary, Wu, Julie T., primary, Xie, Zhuoer, primary, Yeh, Albert C., primary, Zhu, Huili, primary, Shyr, Yu, primary, Lyman, Gary H., primary, and Warner, Jeremy L., primary

Published
2023
Full Text
View/download PDF

18. Supplementary Data from Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study

Author

Rivera, Donna R., primary, Peters, Solange, primary, Panagiotou, Orestis A., primary, Shah, Dimpy P., primary, Kuderer, Nicole M., primary, Hsu, Chih-Yuan, primary, Rubinstein, Samuel M., primary, Lee, Brendan J., primary, Choueiri, Toni K., primary, de Lima Lopes, Gilberto, primary, Grivas, Petros, primary, Painter, Corrie A., primary, Rini, Brian I., primary, Thompson, Michael A., primary, Arcobello, Jonathan, primary, Bakouny, Ziad, primary, Doroshow, Deborah B., primary, Egan, Pamela C., primary, Farmakiotis, Dimitrios, primary, Fecher, Leslie A., primary, Friese, Christopher R., primary, Galsky, Matthew D., primary, Goel, Sanjay, primary, Gupta, Shilpa, primary, Halfdanarson, Thorvardur R., primary, Halmos, Balazs, primary, Hawley, Jessica E., primary, Khaki, Ali Raza, primary, Lemmon, Christopher A., primary, Mishra, Sanjay, primary, Olszewski, Adam J., primary, Pennell, Nathan A., primary, Puc, Matthew M., primary, Revankar, Sanjay G., primary, Schapira, Lidia, primary, Schmidt, Andrew, primary, Schwartz, Gary K., primary, Shah, Sumit A., primary, Wu, Julie T., primary, Xie, Zhuoer, primary, Yeh, Albert C., primary, Zhu, Huili, primary, Shyr, Yu, primary, Lyman, Gary H., primary, and Warner, Jeremy L., primary

Published
2023
Full Text
View/download PDF

21. Care disruptions among patients with lung cancer: A COVID-19 and cancer outcomes study

Author

Bhalla, Sheena, Bakouny, Ziad, Schmidt, Andrew L., Labaki, Chris, Steinharter, John A., Tremblay, Douglas A., Awad, Mark M., Kessler, Alaina J., Haddad, Robert I., Evans, Michelle, Busser, Fiona, Wotman, Michael, Curran, Catherine R., Zimmerman, Brittney S., Bouchard, Gabrielle, Jun, Tomi, Nuzzo, Pier V., Qin, Qian, Hirsch, Laure, Feld, Jonathan, Kelleher, Kaitlin M., Seidman, Danielle, Huang, Hsin-Hui, Anderson-Keightly, Heather M., El Zarif, Talal, Abou Alaiwi, Sarah, Rosenbloom, Talia D., Stewart, Penina S., Galsky, Matthew D., Choueiri, Toni K., and Doroshow, Deborah B.

Published
2021
Full Text
View/download PDF

22. Abstract S06-02: Disruption to care of patients with thoracic malignancies: A COVID-19 and cancer outcomes study

Author

Bhalla, Sheena, primary, Bakouny, Ziad, additional, Schmidt, Andrew L., additional, Steinharter, John A., additional, Tremblay, Douglas A., additional, Awad, Mark M., additional, Kessler, Alaina J., additional, Haddad, Robert I., additional, Evans, Michelle, additional, Busser, Fiona, additional, Wotman, Michael, additional, Curran, Catherine R., additional, Zimmerman, Brittney S., additional, Bouchard, Gabrielle, additional, Jun, Tomi, additional, Nuzzo, Pier V., additional, Qin, Qian, additional, Hirsch, Laure, additional, Feld, Jonathan, additional, Kelleher, Kaitlin M, additional, Seidman, Danielle, additional, Huang, Hsin-Hui, additional, Labaki, Chris, additional, Anderson-Keightly, Heather M., additional, Alaiwi, Sarah Abou, additional, Rosenbloom, Talia D., additional, Stewart, Penina S., additional, Galsky, Matthew D., additional, Choueiri, Toni K., additional, and Doroshow, Deborah B., additional

Published
2021
Full Text
View/download PDF

23. Cancer Care Disparities during the COVID-19 Pandemic: COVID-19 and Cancer Outcomes Study

Author

Schmidt, Andrew L., primary, Bakouny, Ziad, additional, Bhalla, Sheena, additional, Steinharter, John A., additional, Tremblay, Douglas A., additional, Awad, Mark M., additional, Kessler, Alaina J., additional, Haddad, Robert I., additional, Evans, Michelle, additional, Busser, Fiona, additional, Wotman, Michael, additional, Curran, Catherine R., additional, Zimmerman, Brittney S., additional, Bouchard, Gabrielle, additional, Jun, Tomi, additional, Nuzzo, Pier V., additional, Qin, Qian, additional, Hirsch, Laure, additional, Feld, Jonathan, additional, Kelleher, Kaitlin M., additional, Seidman, Danielle, additional, Huang, Hsin-Hui, additional, Anderson-Keightly, Heather M., additional, Abou Alaiwi, Sarah, additional, Rosenbloom, Talia D., additional, Stewart, Penina S., additional, Galsky, Matthew D., additional, Choueiri, Toni K., additional, and Doroshow, Deborah B., additional

Published
2020
Full Text
View/download PDF

24. A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance

Author

Abidi, Maheen, primary, Aboulafia, David M., additional, Accordino, Melissa K., additional, Acoba, Jared D., additional, Ahluwalia, Manmeet S., additional, Ahmad, Syed A., additional, Ajmera, Archana, additional, Alimohamed, Saif I., additional, Altman, Jessica, additional, Angevine, Anne H., additional, Bakouny, Ziad, additional, Bar, Michael H., additional, Bardia, Aditya, additional, Barnholtz-Sloan, Jill S., additional, Barrow McCollough, Briana, additional, Bashir, Babar, additional, Batist, Gerald, additional, Bekaii-Saab, Tanios S., additional, Berg, Stephanie, additional, Bernicker, Eric H., additional, Bhutani, Divaya, additional, Bilen, Mehmet A., additional, Bindal, Poorva, additional, Bishnoi, Rohit, additional, Blau, Sibel, additional, Bohachek, Pamela, additional, Boland, Genevieve, additional, Bonnen, Mark, additional, Bouchard, Gabrielle, additional, Bouganim, Nathaniel, additional, Bowles, Daniel W., additional, Busser, Fiona J., additional, Butt, Omar, additional, Cabal, Angelo, additional, Cabalona, Wilhelmina D., additional, Cabebe, Elwyn C., additional, Caimi, Paolo, additional, Campian, Jian L., additional, Carducci, Theresa M., additional, Chen, James L., additional, Cheng, Alex, additional, Chism, David D., additional, Choueiri, Toni K., additional, Clark, Melanie J., additional, Clement, Jessica M., additional, Connors, Jean M., additional, Cook, Erin, additional, Curran, Catherine R., additional, Daher, Ahmad, additional, Dailey, Mark E., additional, Davis, Elizabeth J., additional, Dawsey, Scott J., additional, Deeken, John F., additional, Del Prete, Salvatore A., additional, Demetri, George D., additional, Desai, Aakash, additional, Doroshow, Deborah B., additional, Durbin, Eric B., additional, Egan, Pamela C., additional, Elias, Rawad, additional, Elkrief, Arielle, additional, Elms, Destry J., additional, Elshoury, Amro, additional, Faller, Bryan, additional, Farmakiotis, Dimitrios, additional, Fecher, Leslie A., additional, Feldman, Lawrence E., additional, Ferrario, Cristiano, additional, Fiala, Mark A., additional, Flora, Daniel B., additional, French, Benjamin, additional, Friese, Christopher R., additional, Fu, Julie C., additional, Gadgeel, Shirish M., additional, Gainor, Justin, additional, Galsky, Matthew D., additional, Gantt, Gerald, additional, Garcia, Jorge A., additional, Gartrell, Benjamin A., additional, Gatti-Mays, Margaret E., additional, Gill, David M., additional, Gillaspie, Erin A., additional, Giordano, Antonio, additional, Glace, (Mary) Grace, additional, Glover, Michael J., additional, Goel, Sanjay, additional, Graber, Jerome J., additional, Griffiths, Elizabeth A., additional, Grivas, Petros, additional, Grover, Punita, additional, Gulati, Anthony P., additional, Gulati, Shuchi, additional, Gupta, Shilpa, additional, Gurley, Michael, additional, Hafez, Navid, additional, Halabi, Susan, additional, Halfdanarson, Thorvardur R., additional, Halmos, Balazs, additional, Hausrath, Daniel J., additional, Hawley, Jessica E., additional, Hennessy, Cassandra, additional, Herbst, Roy S., additional, Hershman, Dawn L., additional, Hoppenot, Claire, additional, Hoskins, Kent F., additional, Hoyo-Ulloa, Irma, additional, Hsu, Emily, additional, Hsu, Chih-Yuan, additional, Hwang, Clara, additional, Islam, Jessica Yasmine, additional, Jabbour, Salma K., additional, Jani, Chinmay, additional, Jha, Alokkumar, additional, Jhawar, Sachin R., additional, Johnson, Douglas B., additional, Joshi, Monika, additional, Kasi, Anup, additional, Kelleher, Kaitlin, additional, Kennecke, Hagen F., additional, Khaki, Ali Raza, additional, Khan, Hina, additional, Khan, Mahir, additional, Kharofa, Jordan, additional, Kloecker, Goetz, additional, Knoble, Jeanna L., additional, Kulkarni, Amit A., additional, Kumar, Vaibhav, additional, Lammers, Philip E., additional, Leighton, John C., additional, Lemmon, Christopher A., additional, Lewis, Mark A., additional, Li, Ang, additional, Li, Xuanyi, additional, Liu, Stephen V., additional, Lo, K.M., additional, Loaiza-Bonilla, Arturo, additional, Logan, Barbara B., additional, Loggers, Elizabeth T., additional, de Lima Lopes, Gilberto, additional, Loree, Jonathan M., additional, LoRusso, Patricia, additional, Low, Clarke A., additional, Lustberg, Maryam B., additional, Lyman, Gary H., additional, Lynch, Ryan C., additional, Madhavan, Subha, additional, Mahadevan, Daruka, additional, Mahmood, Sana Z., additional, Mansoor, Abdul-Hai, additional, Marcum, Michelle, additional, Markham, Merry-Jennifer, additional, Mashru, Sandeep H., additional, Masters, Tyler, additional, Mavromatis, Blanche H., additional, McKay, Rana R., additional, McNair, Christopher, additional, McWeeney, Shannon, additional, Menendez, Alvaro G., additional, Menon, Harry, additional, Mesa, Ruben A., additional, Mico, Vasil, additional, Miller, Chaim, additional, Mishra, Sanjay, additional, Monahan, Ryan S., additional, Morgans, Alicia K., additional, Mulcahy, Mary F., additional, Mundt, Daniel, additional, Mushtaq, Sarah, additional, Nagaraj, Gayathri, additional, Nagle, Sarah, additional, Nakasone, Elizabeth S., additional, Nakayama, John M., additional, Nelson, Heather H., additional, Nemecek, Eneida R., additional, Nguyen, Ryan H., additional, Nizam, Amanda, additional, Nohria, Anju, additional, Nuzzo, Pier Vitale, additional, Ohri, Nitin, additional, Olszewski, Adam J., additional, Owenby, Susie, additional, Painter, Corrie A., additional, Palmer, Joshua D., additional, Panagiotou, Orestis A., additional, Park, Cathleen, additional, Pasquinelli, Mary M., additional, Patel, Jaymin M., additional, Patel, Kanishka G., additional, Peddi, Prakash, additional, Pennell, Nathan A., additional, Peters, Solange, additional, Pilar, Christine, additional, Pillainayagam, Clement, additional, Puc, Matthew, additional, Ramirez, Amelie G., additional, Rathmann, Joerg, additional, Ravindranathan, Deepak, additional, Reid, Sonya A., additional, Reuben, Daniel Y., additional, Revankar, Sanjay G., additional, Reynolds, Kerry L., additional, Rho, Young Soo, additional, Rhodes, Terence D., additional, Rice, Robert L., additional, Riess, Jonathan, additional, Rini, Brian I., additional, Rink, Cameron, additional, Rosen, Lane R., additional, Rosenstein, Lori J., additional, Rosovsky, Rachel P., additional, Routy, Bertrand, additional, Rovito, Marc A., additional, Rubinstein, Samuel M., additional, Saif, M. Wasif, additional, Salazar, Mary, additional, Santos Dutra, Miriam, additional, Schapira, Lidia, additional, Schmidt, Andrew L., additional, Schroeder, Brett A., additional, Schwartz, Gary K., additional, Schwartz, Candice, additional, Schweizer, Michael T., additional, Serrano, Oscar K., additional, Shafer, Danielle A., additional, Shah, Pankil K., additional, Shah, Dimpy, additional, Shah, Mansi R., additional, Shah, Sumit A., additional, Shah, Chintan, additional, Shaw, Grace, additional, Shaya, Justin A., additional, Shyr, Yu, additional, Slosky, David A., additional, Smits, Melissa, additional, Solorzano, Carmen C., additional, Stauffer, Karen, additional, Stockerl-Goldstein, Keith E., additional, Stover, Daniel G., additional, Stratton, Jamie, additional, Stratton, Catherine, additional, Streckfuss, Mitrianna, additional, Subbiah, Suki, additional, Tachiki, Lisa, additional, Tadesse, Eyob, additional, Thompson, Michael A., additional, Topaloglu, Umit, additional, Tucker, Matthew D., additional, Van Allen, Eliezer M., additional, Van Loon, Susan, additional, Vega-Luna, Karen, additional, Venepalli, Neeta K., additional, Verma, Amit, additional, Vikas, Praveen, additional, Vinayak, Shaveta, additional, Vinh, Donald C., additional, Wagner, Michael J., additional, Wall, Sarah, additional, Wang, Lucy L., additional, Warner, Jeremy L., additional, Wehbe, Firas H., additional, Weinstein, Paul L., additional, Weiss, Matthias, additional, Weissmann, Lisa B., additional, Wildes, Tanya M., additional, Williams, Nicole, additional, Wise-Draper, Trisha M., additional, Wood, William A., additional, Wu, Julie Tsu-Yu, additional, Wulff-Burchfield, Elizabeth M., additional, Xie, Zhuoer, additional, Xu, Wenxin, additional, Yeh, Albert C., additional, Yu, Irene S., additional, Yu, Peter Paul, additional, Zacks, Rosemary, additional, Zaman, Qamar Ul, additional, Zaren, Howard, additional, Zhang, Tian, additional, Zhou, Alice Y., additional, Zhu, Huili, additional, Zon, Rebecca L., additional, and Zubiri, Leyre, additional

Published
2020
Full Text
View/download PDF

25. Survey of the Impact of COVID-19 on Oncologists’ Decision Making in Cancer

Author

Ürün, Yüksel, primary, Hussain, Syed A., additional, Bakouny, Ziad, additional, Castellano, Daniel, additional, Kılıçkap, Saadettin, additional, Morgan, Gilberto, additional, Mckay, Rana R., additional, Pels, Kevin, additional, Schmidt, Andrew, additional, Doroshow, Deborah B., additional, Schütz, Fábio, additional, Albiges, Laurence, additional, Lopes, Gilberto, additional, Catto, James W. F., additional, Peters, Solange, additional, and Choueiri, Toni K., additional

Published
2020
Full Text
View/download PDF

26. Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study

Author

Rivera, Donna R., primary, Peters, Solange, additional, Panagiotou, Orestis A., additional, Shah, Dimpy P., additional, Kuderer, Nicole M., additional, Hsu, Chih-Yuan, additional, Rubinstein, Samuel M., additional, Lee, Brendan J., additional, Choueiri, Toni K., additional, de Lima Lopes, Gilberto, additional, Grivas, Petros, additional, Painter, Corrie A., additional, Rini, Brian I., additional, Thompson, Michael A., additional, Arcobello, Jonathan, additional, Bakouny, Ziad, additional, Doroshow, Deborah B., additional, Egan, Pamela C., additional, Farmakiotis, Dimitrios, additional, Fecher, Leslie A., additional, Friese, Christopher R., additional, Galsky, Matthew D., additional, Goel, Sanjay, additional, Gupta, Shilpa, additional, Halfdanarson, Thorvardur R., additional, Halmos, Balazs, additional, Hawley, Jessica E., additional, Khaki, Ali Raza, additional, Lemmon, Christopher A., additional, Mishra, Sanjay, additional, Olszewski, Adam J., additional, Pennell, Nathan A., additional, Puc, Matthew M., additional, Revankar, Sanjay G., additional, Schapira, Lidia, additional, Schmidt, Andrew, additional, Schwartz, Gary K., additional, Shah, Sumit A., additional, Wu, Julie T., additional, Xie, Zhuoer, additional, Yeh, Albert C., additional, Zhu, Huili, additional, Shyr, Yu, additional, Lyman, Gary H., additional, and Warner, Jeremy L., additional

Published
2020
Full Text
View/download PDF

29. Wassermann Before Wedding Bells: Premarital Examination Laws in the United States, 1937–1950.

Author

Doroshow, Deborah B

Subjects
MARRIAGE licenses, SYPHILIS, BLOOD testing, STATE laws, PUBLIC health, COMMUNICABLE diseases
Abstract

In the late 1930s, states began to pass laws requiring men and women applying for marriage licences to demonstrate proof of a blood test showing that they did not harbour communicable syphilis. Advocates of the laws positioned marriage as a public health checkpoint to identify new cases of syphilis as part of a broader effort to approach the disease as a public health problem, rather than a moral one. Although the laws appeared to have broad popular support, in reality they were a failed public health intervention. Couples rushed to the altar before laws went into effect and border-hopped to marry in states without blood test laws. The blood tests used to detect syphilis were difficult to interpret and physicians could not agree on a standard definition of communicable disease. But for over 30 years, premarital examination laws represented a tangible government presence in the private lives of most Americans. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

32. Financial Toxicity Among Patients With Advanced Solid Tumors Participating in Early-Phase Clinical Trials

Author

Blanter, Julia, Van Hyfte, Grace, Ahmad, Maham, Xu, Suzanne, Hapanowicz, Olivia, Fazilov, Gabriela, Lu, Ashley, Lucas, Natalie, Wu, Kathy, Shelton, Gary, DeMerchant, Mandy, Lachowicz, Michael, Kier, Melanie, Werner, Michael, Eder, Joseph P., Galsky, Matthew D., Marron, Thomas U., Smith, Cardinale B., LoRusso, Patricia M., Hofstatter, Erin, and Doroshow, Deborah B.

Published
2024
Full Text
View/download PDF

33. Systemic Anticancer Therapy and Thromboembolic Outcomes in Hospitalized Patients With Cancer and COVID-19.

Author

Gulati S, Hsu CY, Shah S, Shah PK, Zon R, Alsamarai S, Awosika J, El-Bakouny Z, Bashir B, Beeghly A, Berg S, de-la-Rosa-Martinez D, Doroshow DB, Egan PC, Fein J, Flora DB, Friese CR, Fromowitz A, Griffiths EA, Hwang C, Jani C, Joshi M, Khan H, Klein EJ, Heater NK, Koshkin VS, Kwon DH, Labaki C, Latif T, McKay RR, Nagaraj G, Nakasone ES, Nonato T, Polimera HV, Puc M, Razavi P, Ruiz-Garcia E, Saliby RM, Shastri A, Singh SRK, Tagalakis V, Vilar-Compte D, Weissmann LB, Wilkins CR, Wise-Draper TM, Wotman MT, Yoon JJ, Mishra S, Grivas P, Shyr Y, Warner JL, Connors JM, Shah DP, and Rosovsky RP

Subjects
Humans, Male, Aged, Female, Anticoagulants therapeutic use, Cohort Studies, Retrospective Studies, COVID-19 Testing, Vascular Endothelial Growth Factor A, SARS-CoV-2, Immunomodulating Agents, COVID-19, Venous Thromboembolism chemically induced, Venous Thromboembolism epidemiology, Neoplasms complications, Neoplasms drug therapy, Neoplasms epidemiology
Abstract

Importance: Systematic data on the association between anticancer therapies and thromboembolic events (TEEs) in patients with COVID-19 are lacking., Objective: To assess the association between anticancer therapy exposure within 3 months prior to COVID-19 and TEEs following COVID-19 diagnosis in patients with cancer., Design, Setting, and Participants: This registry-based retrospective cohort study included patients who were hospitalized and had active cancer and laboratory-confirmed SARS-CoV-2 infection. Data were accrued from March 2020 to December 2021 and analyzed from December 2021 to October 2022., Exposure: Treatments of interest (TOIs) (endocrine therapy, vascular endothelial growth factor inhibitors/tyrosine kinase inhibitors [VEGFis/TKIs], immunomodulators [IMiDs], immune checkpoint inhibitors [ICIs], chemotherapy) vs reference (no systemic therapy) in 3 months prior to COVID-19., Main Outcomes and Measures: Main outcomes were (1) venous thromboembolism (VTE) and (2) arterial thromboembolism (ATE). Secondary outcome was severity of COVID-19 (rates of intensive care unit admission, mechanical ventilation, 30-day all-cause mortality following TEEs in TOI vs reference group) at 30-day follow-up., Results: Of 4988 hospitalized patients with cancer (median [IQR] age, 69 [59-78] years; 2608 [52%] male), 1869 had received 1 or more TOIs. Incidence of VTE was higher in all TOI groups: endocrine therapy, 7%; VEGFis/TKIs, 10%; IMiDs, 8%; ICIs, 12%; and chemotherapy, 10%, compared with patients not receiving systemic therapies (6%). In multivariable log-binomial regression analyses, relative risk of VTE (adjusted risk ratio [aRR], 1.33; 95% CI, 1.04-1.69) but not ATE (aRR, 0.81; 95% CI, 0.56-1.16) was significantly higher in those exposed to all TOIs pooled together vs those with no exposure. Among individual drugs, ICIs were significantly associated with VTE (aRR, 1.45; 95% CI, 1.01-2.07). Also noted were significant associations between VTE and active and progressing cancer (aRR, 1.43; 95% CI, 1.01-2.03), history of VTE (aRR, 3.10; 95% CI, 2.38-4.04), and high-risk site of cancer (aRR, 1.42; 95% CI, 1.14-1.75). Black patients had a higher risk of TEEs (aRR, 1.24; 95% CI, 1.03-1.50) than White patients. Patients with TEEs had high intensive care unit admission (46%) and mechanical ventilation (31%) rates. Relative risk of death in patients with TEEs was higher in those exposed to TOIs vs not (aRR, 1.12; 95% CI, 0.91-1.38) and was significantly associated with poor performance status (aRR, 1.77; 95% CI, 1.30-2.40) and active/progressing cancer (aRR, 1.55; 95% CI, 1.13-2.13)., Conclusions and Relevance: In this cohort study, relative risk of developing VTE was high among patients receiving TOIs and varied by the type of therapy, underlying risk factors, and demographics, such as race and ethnicity. These findings highlight the need for close monitoring and perhaps personalized thromboprophylaxis to prevent morbidity and mortality associated with COVID-19-related thromboembolism in patients with cancer.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results